What Is Emend and What Does It Treat?
Emend (fosaprepitant dimeglumine for injection or aprepitant oral capsules) is an antiemetic medication that blocks substance P from binding to NK1 receptors in the brain, preventing nausea and vomiting. It specifically targets chemotherapy-induced nausea and vomiting (CINV), a common side effect of cancer treatments like cisplatin or other highly emetogenic chemo drugs.[1]
Does Emend Help with Chemo Side Effects?
Yes, Emend effectively reduces acute and delayed nausea and vomiting from chemo when used with other antiemetics like ondansetron (a 5-HT3 blocker) and dexamethasone (a corticosteroid). Clinical trials showed it cut complete response rates (no vomiting, no rescue meds) to 71-74% in the delayed phase versus 48-52% with standard therapy alone.[1][2] It's FDA-approved for moderate-to-high emetogenic chemo in adults and kids over 6 months.
How Is Emend Given for Chemo?
A single IV dose of 150 mg fosaprepitant on day 1, paired with oral ondansetron and dexamethasone, followed by oral aprepitant (80 mg days 2-3) if needed. This regimen covers both acute (first 24 hours) and delayed (up to 5 days) CINV.[1]
What Other Chemo Side Effects Does It Help?
Emend focuses on nausea and vomiting; it does not treat fatigue, hair loss, neuropathy, mouth sores, diarrhea, or low blood counts. Guidelines from ASCO and NCCN recommend it only for CINV prevention, not other symptoms.[2][3]
Common Side Effects of Emend Itself
Fatigue (15%), diarrhea (13%), constipation (12%), headache, and hiccups. Rare risks include allergic reactions or liver enzyme changes. It's metabolized by CYP3A4, so it interacts with drugs like warfarin or hormonal birth control.[1]
How Does Emend Compare to Other Antiemetics?
| Drug/Regimen | Acute CINV Control | Delayed CINV Control | Dosing Convenience |
|--------------|---------------------|-----------------------|-------------------|
| Emend + ondansetron + dex | 89% | 71-74% | Single IV + 2 oral days |
| Ondansetron + dex alone | 78% | 48-52% | Oral/IV daily |
| Rolapitant (Varubi) + standard | 87% | 72% | Single oral dose |
| Netupitant/palonosetron (Akynzeo) | 90% | 78% | Single oral dose |
Emend excels in delayed phase but requires multi-day dosing unlike single-dose rivals.[2][4]
Who Should Avoid Emend?
Patients with severe liver issues, hypersensitivity to aprepitant, or on strong CYP3A4 inhibitors/inducers. Not studied in pregnancy (category B); use backup contraception.[1]
When Does Emend's Patent Expire?
Key patents on aprepitant expired in 2026 in the US, allowing generics; fosaprepitant patents run to 2027-2030 depending on formulation. Check DrugPatentWatch.com for latest litigation and ANDA filings.[5]
[1]: Emend Prescribing Information, Merck (FDA label, 2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021549s045lbl.pdf
[2]: Hesketh et al., J Clin Oncol (2003); NCCN Antiemesis Guidelines v2.2024.
[3]: ASCO CINV Guidelines (2020).
[4]: Schwartzberg et al., Ann Oncol (2015).
[5]: DrugPatentWatch.com, Emend patents. https://www.drugpatentwatch.com/p/tradename/EMEND